What is Macomics?
Founded in 2019, Macomics operates at the intersection of immunology and oncology, leveraging deep expertise in macrophage biology to develop precision medicines. By targeting disease-specific tumor-associated macrophages (TAMs), the company addresses critical gaps in current cancer treatment paradigms. Its core technology platform facilitates the identification and validation of novel therapeutic targets, providing a robust pipeline of antibody programs. As a leader in the Scottish life sciences ecosystem, Macomics maintains a strategic focus on translating academic excellence from the University of Edinburgh into scalable, high-impact clinical solutions for oncology patients worldwide.
How much funding has Macomics raised?
Macomics has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2021): $5.9M with participation from Caribou Property Limited, Scottish Enterprise, and Epidarex Capital
Key Investors in Macomics
Epidarex Capital
A transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, utilizing deep scientific networks to support early-stage biopharmaceutical innovation.
Scottish Enterprise
The national economic development agency of the Scottish Government, dedicated to fostering innovation and economic growth within Scotland's key industrial sectors.
Caribou Property Limited
A private investment entity participating in the funding round to support the advancement of precision oncology research.
What's next for Macomics?
The infusion of capital will serve as a catalyst for Macomics to accelerate its antibody programs toward clinical trials. Strategic priorities include the expansion of its therapeutic portfolio and continued investment in its target discovery technology to maintain a competitive edge in the biopharmaceutical sector. By scaling its operational capabilities, the company aims to solidify its position as a pioneer in macrophage-based therapies, potentially transforming the standard of care for complex malignancies. Future growth will likely involve deepening partnerships with global pharmaceutical entities to facilitate the commercialization of its lead candidates.
See full Macomics company page
